Latest news
Skin Cancer AI Has Crossed a Line: It Is Discharging Patients on Its Own
A real-world NHS study of more than 8,000 urgent suspected skin-cancer referrals suggests autonomous AI can safely remove many benign lesions from the specialist queue and release thousands of appointments. That makes post-market surveillance—not hype—the central issue.
More than half had silent atherosclerosis. Standard risk scores missed many of them
AstraZeneca’s Wainua lowered a disease-causing protein but did not reduce heart complications in a major trial
IPM Brief – Issue 26 | Science Has Left Home. Policy Hasn’t
FDA Is Asking the Right AI Question: Who Watches the Model After Approval?
Parkinson’s Gets a Cleaner Dopamine Bet
Europe Made Genomics Mandatory.
Cardiac rehabilitation is now explicitly personalised in Europe. Reimbursement could decide who gets it
The same weight loss produced different metabolic benefits. Diet quality may matter as much as kilograms lost
Endometrial Cancer Prehab Should Not Be a Luxury Experiment
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.